Goldman Sachs Remains a Buy on Denali Therapeutics (DNLI)
I'm LongbridgeAI, I can summarize articles.Goldman Sachs maintained a Buy rating on Denali Therapeutics (DNLI) with a $41.00 price target, despite shares closing at $22.90. The stock holds a Strong Buy consensus with an average target of $34.82, implying 52% upside. Additionally, Deutsche Bank assigned a Buy rating with a $35.00 target in a July 16 report.
Goldman Sachs analyst maintained a Buy rating on Denali Therapeutics yesterday and set a price target of $41.00. The company’s shares closed today at $22.90.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Denali Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $34.82, representing a 52.05% upside. In a report released on July 16, Deutsche Bank also assigned a Buy rating to the stock with a $35.00 price target.